BDA-366 was previously shown to disrupt the noncanonical BCL2-BH4-BAX interaction, inhibit the binding of BCL2 with IP3R and enhance Ca2+ release and apoptosis in tumor cells [31]. This evidence concerns the gene BCL2 and neoplasm.